GoldenGolden
T2 Biosystems

T2 Biosystems

T2 Biosystems is a Lexington, Massachusetts-based company developing diagnostic products targeting sepsis and in vitro diagnostic products intended to target sepsis, hemostasis, bacteria, and lyme disease founded in 2006 by Robin Toft.

T2 Biosystems is a company that is known for developing products that treat life altering diseases. The solutions that they have developed were created with the purpose of saving lives and reducing the healthcare costs for patients and caregivers.

Some of the products and solutions that T2 Biosystems has developed includes their T2 Biosystems, T2MR, T2Bacteria Panel, T2Candida Panel, and T2Dx. They are also developing their T2Direct Diagnostics, T2HemoStat, T2Plex, T2Cauris, T2Resistance, and T2SARS-CoV-2 in their pipeline.

Innovating solutions to treat against diseases such as sepsis, hemostasis, and bacterial and Lyme disease is possible through the company's T2MR method. T2MR is a method that utilizes miniaturized magnetic resonance technology to measure the reaction of water molecules that are present around a magnetic field. The method does not require purification or extraction of target molecules in order to identify those target molecules.

The number of cells that is required for the T2MR to detect target cells or organism in a blood culture can be as low as 1 CFU/mL, as opposed to the standard range of 10,000 to 1,000,000 CFUs/mL. This property of the method allows the T2MR to detect low levels of pathogens in whole blood.

Timeline

September 2019
T2 Biosystems raises a $69,000,000 grant from Biomedical Advanced Research and Development Authority.
March 2018
T2 Biosystems raises a $2,000,000 grant from Carb-X.
December 2016
T2 Biosystems raises a $50,000,000 venture round from Capital Royalty Group.
September 2016
T2 Biosystems raises a $40,000,000 venture round from Canon.com/ijsetup - Ij.start.canon.
March 28, 2013
T2 Biosystems raises a $40,000,000 series E round from Aisling Capital, Arcus Ventures, Camros Capital, Flagship Pioneering, Flybridge Capital Partners, Goldman Sachs, Partners Healthcare Group, Physic Ventures, Polaris Partners and WS Investments.
August 10, 2011
T2 Biosystems raises a $23,000,000 series D round from Aisling Capital, Arcus Ventures, Camros Capital, Flagship Pioneering, Flybridge Capital Partners, Partners HealthCare, Physic Ventures, Polaris Partners, RA Capital Management and WS Investments.
May 26, 2010
T2 Biosystems raises a $15,000,000 series C round from Arcus Ventures, Camros Capital, Flagship Pioneering, Flybridge Capital Partners, Partners HealthCare, Physic Ventures, Polaris Partners, RA Capital Management and WS Investments.
October 2008
T2 Biosystems raises a $10,800,000 series B round from Flagship Pioneering, Flybridge Capital Partners, In-Q-Tel, Partners HealthCare and Polaris Partners.
May 2008
T2 Biosystems raises a $500,000 convertible note from Flybridge Capital Partners.
2006
T2 Biosystems was founded by Lee Josephson, Michael Cima, Robin Toft and Tyler Jacks.
Page 1 of 2

Funding rounds

Funding round
Funding type
Funding round amount (USD)
Funding round date
Investment
T2 Biosystems Series E round
40,000,000
March 28, 2013
10 Results
Results per page:
Page 1 of 1

People

Name
Role
LinkedIn

Alisha Patrick

Employee

Andy Donner

Investor

Blesson Abraham John

Employee

Brendan Manning

Employee

Chris Werner, PMP

Employee

Daniella Lynn Logan

Employee

David Aronoff

Board member

Eugenio Daviso

Employee

Jennifer Gordon

Employee

Joe Peine

Employee

John Hughes

Employee

Jon Nolz

Employee

Jordan Raphel

Employee

Joseph Schaefer

Employee

Marc Jones

Employee

Mark Kieras

Employee

Megan Luna

Employee

Michael AaRaimo

Employee

Michael Min

Employee

Stacy Feld

Investor

Stan Lapidus

Employee

Stephana Petrino

Employee

Zhixiang (Jeffrey) Luo

Employee

Further reading

Title
Author
Link
Type
Date

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.